United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of “Moderate Buy” by Analysts

United Therapeutics Corporation (NASDAQ:UTHR) has received an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $646.00.

Several brokerages recently commented on UTHR. Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada upped their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,851,434.88. This represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 603,218 shares of company stock worth $339,413,656 in the last quarter. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 0.3%

UTHR stock opened at $552.48 on Friday. United Therapeutics has a 12-month low of $272.12 and a 12-month high of $609.35. The stock has a market cap of $23.45 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.82 and a beta of 0.58. The business’s 50-day moving average is $557.18 and its 200 day moving average is $529.32.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 earnings per share. As a group, equities analysts forecast that United Therapeutics will post 26.63 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.